Replimune and Incyte Enter into Clinical Trial Collaboration and Supply Agreement to Evaluate RP1 and INCB99280 in Patients with Cutaneous Squamous Cell Carcinoma August 9, 2023
CG Oncology Announces $105 Million Oversubscribed Crossover Financing to Support Continued Advancement of Clinical-Stage Bladder Cancer Pipeline August 9, 2023
Horizon Technology Finance Provides $15 Million Venture Loan Facility to Tallac Therapeutics August 9, 2023
REZILIENT3 Global First-Line Trial of Zipalertinib Launched in Patients With NSCLC Harboring EGFR Exon 20 Insertion Mutations August 9, 2023
Retevmo® (selpercatinib) Demonstrated Superior PFS vs a PD-1 Inhibitor + Chemo for Adults with Newly-Diagnosed Advanced or Metastatic RET Fusion-Positive NSCLC August 9, 2023
U.S. FDA Grants Orphan Drug Designation to ABM-1310 for the Treatment of Patients with Glioblastoma Harboring BRAF V600 Mutation August 9, 2023
FAILED TRIAL: Ph 3 AXLerate-OC Study of Batiraxcept in Platinum-Resistant Ovarian Cancer failed to meet primary endpoint of PFS improvement August 9, 2023
FDA sends CRL for LYMPHIR™ (Denileukin Diftitox) for the Treatment of Patients with R/R CTCL August 9, 2023
European Commission Approves LONSURF® (Trifluridine/tipiracil) in Combination With Bevacizumab in 3rd Line Refractory mCRC August 9, 2023
Jemperli (dostarlimab) + chemo approved in the US as 1L treatment for dMMR/MSI-H primary advanced or recurrent endometrial cancer August 9, 2023
